Twist Bioscience Appoints Steffen Hellmold as Senior Vice President, Business Development, Data Storage
October 12 2021 - 8:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the appointment of
Steffen Hellmold to the newly created position of senior vice
president, business development, data storage.
“We have made significant technological advances in our DNA data
storage division and are now focused on laying the foundation for
commercialization of this disruptive and important storage
solution. The addition of Steffen to the team will help to define
our commercialization strategy and build important relationships as
we move towards more accessible DNA data storage solutions,”
commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist
Bioscience.
Mr. Hellmold joins Twist from Western Digital where, as vice
president of corporate strategic initiatives, he was responsible
for identifying and leading disruptive innovation projects, with a
focus on accessible and deep archive storage solutions.
Before joining Western Digital, Mr. Hellmold was vice president
of marketing at Everspin Technologies. Prior positions include
executive management roles at SandForce, Seagate Technology, Lexar
Media, Samsung Semiconductor, Fujitsu and SMART Modular. He has
been deeply engaged in various industry trade associations and
standards organizations. He co-founded the DNA Data Storage
Alliance as well as the USB Flash Drive Alliance. Mr. Hellmold
holds an Economic Electrical Engineering degree (EEE) from the
Technical University of Darmstadt, Germany.
“Twist has been at the forefront of leveraging DNA as a storage
medium. I believe my background in identifying and developing
solutions to address the growing need for long-term data storage
will support the strategic business objectives of the DNA data
storage division,” said Mr. Hellmold. “I’m excited to join Twist at
this pivotal time with DNA data storage on the precipice of
commercial availability.”
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including but not limited to the commercial availability of
DNA data storage, are forward-looking statements reflecting the
current beliefs and expectations of management made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Such forward-looking statements involve known and
unknown risks, uncertainties, and other important factors that may
cause Twist Bioscience’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the risks and uncertainties of the ability to attract
new customers and retain and grow sales from existing customers;
risks and uncertainties of rapidly changing technologies and
extensive competition in synthetic biology could make the products
Twist Bioscience is developing obsolete or non-competitive; the
retention of employees of acquired companies and the ability of
Twist Bioscience to successfully integrate acquired companies and
to achieve expected benefits, risks of third party claims alleging
infringement of patents and proprietary rights or seeking to
invalidate Twist Bioscience’s patents or proprietary rights; and
the risk that Twist Bioscience’s proprietary rights may be
insufficient to protect its technologies. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to Twist Bioscience’s business in general,
see Twist Bioscience’s risk factors set forth in Twist Bioscience’s
Quarterly Report Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2021 and subsequent filings with the SEC.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211012005413/en/
Angela Bitting SVP, Corporate Affairs 925- 202-6211
media@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Mar 2024 to Apr 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Apr 2023 to Apr 2024